GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
WASHINGTON, April 11, 2016 -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use of safe and effective regenerative cell therapies in the United States. The April 12th event, Advancing a New Policy Framework for Regenerative Cell Therapy—which begins at 9:30am EST and will be webcast live—will bring together scientific and academic experts, patients, practitioners, and industry to discuss the science behind cell therapy and new policies needed to modernize the current U.S. regulatory approach.
In addition to co-hosting the event, the Regenerative Medicine Foundation is collaborating with BPC to convene and engage a broad societal-based alliance of non-profit patient groups, medical philanthropies, academic centers, industry organizations, and other advocates to support a new regulatory pathway for safe and effective cell therapies in the U.S.
"With the recent introduction of the bipartisan, bicameral REGROW Act, the time has arrived for us to move from laboratories into the clinic," said Bernie Siegel, executive director of the Regenerative Medicine Foundation and founder and chair of the annual World Stem Cell Summit & RegMed Capital Conference. "Cell therapies are different from drugs, and they have the vast potential to alleviate human suffering. We need to support the FDA in accelerating safe and effective cell therapy treatments, and the Regenerative Medicine Foundation is committed to this humanitarian cause."
"We are delighted to be working with the Regenerative Medicine Foundation to advance regenerative cell therapy—which represents one of the most promising areas for the next generation of groundbreaking treatments," said Janet Marchibroda, director of BPC's health innovation initiative. "Through our work together, we are advancing public policy that will accelerate the availability of safe and effective treatments for Americans and improve U.S. competitiveness in the global marketplace."
About the Regenerative Medicine Foundation
The nonprofit Regenerative Medicine Foundation, formerly known as the Genetics Policy Institute, is an influential global network of stakeholders from patient-advocacy, science, and industry that serves as a catalyst and provides leadership to the pro-cures movement. Through RMF's action network, reports, newsletters, the flagship World Stem Cell Summit and RegMed Capital Conference, special projects, speaking engagements, world-renowned advisory boards, educational resources, teaching initiatives, and strategic relationships, RMF serves as the foremost channel of knowledge between leading regenerative medicine experts, patient advocates, and those who make policy for the general public.
CONTACT: Alan Fernandez
650-759-8300
[email protected]
